Cargando…
Immunogenicity and Blocking Efficacy of Norovirus GII.4 Recombinant P Protein Vaccine
Noroviruses (NoVs) are the main cause of acute gastroenteritis in all ages worldwide. The aim of this study was to produce the recombinant P protein of norovirus and to demonstrate its blocking effect. In this study, the engineered strains were induced to express the P protein of NoVs GII.4, which w...
Autores principales: | Yu, Zhendi, Shao, Qingyi, Xu, Zhangkai, Chen, Chenghao, Li, Mingfan, Jiang, Yi, Cheng, Dongqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305070/ https://www.ncbi.nlm.nih.gov/pubmed/37376442 http://dx.doi.org/10.3390/vaccines11061053 |
Ejemplares similares
-
Recombinant GII.P16-GII.2 Norovirus, Taiwan, 2016
por: Liu, Luke Tzu-Chi, et al.
Publicado: (2017) -
Association of GII.P16-GII.2 Recombinant Norovirus Strain with Increased Norovirus Outbreaks, Guangdong, China, 2016
por: Lu, Jing, et al.
Publicado: (2017) -
Emergence of new recombinant noroviruses GII.p16-GII.4 and GII.p16-GII.2, France, winter 2016 to 2017
por: Bidalot, Maxime, et al.
Publicado: (2017) -
Report of Recombinant Norovirus GII.g/GII.12 in Beijing, China
por: Sang, Shaowei, et al.
Publicado: (2014) -
Recombinant GII.Pe-GII.4 Norovirus, Thailand, 2017–2018
por: Chuchaona, Watchaporn, et al.
Publicado: (2019)